
About Casper Pharma Private Limited
Data last updated:
Casper Pharma Private Limited was a private limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Suven Pharmaceuticals Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 January 2016.
The company was registered with the Registrar of Companies (ROC), Mumbai, under CIN U24233MH2016PTC423891. Its GSTIN is 36AAGCC3439C1ZY (Telangana). The company held 2 GST registrations, all of them active.
The company had an authorised share capital of ₹26.1 Cr and a paid-up capital of ₹26.08 Cr. It was led by directors including Sudhir Kumar Singh (Whole-Time Director) and Venkatanaga Kali Vetukuri Vara Prasada Raju.
Its last annual general meeting (AGM) was held on 01 August 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at Mumbai, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹30.43 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹8.34 Cr (net margin -27.4%) and EBITDA of -₹2.51 Cr (EBITDA margin -8.3%). Revenue has grown at a compounded annual rate (CAGR) of 71% over three years and 32% over five years.
The company had about 109 employees on its provident fund (EPFO) records before it was dissolved.
Court records list 1 case involving the company, including 1 filed by the company. The company has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Puneet Laboratories Private Limited with revenue of ₹30.72 Cr. The company has 4 MSME Form 1 returns on record between 2020 and 2022, listing 42 overdue payments to 5 micro and small suppliers.
The last known website on record is cronuspharma.com.
Company details
CIN history
Casper Pharma has one previous CIN (Corporate Identification Number): U24233TG2016PTC102713. The current CIN is U24233MH2016PTC423891, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24233MH2016PTC423891 | Current |
| U24233TG2016PTC102713 | Previous |
Contact details
Casper Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is cronuspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address215 Atrium C Wing 8th Floor 819 – 821, Andheri Kurla Road Chakala Andheri East, Mumbai, Maharashtra, India – 400093
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Casper Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Casper Pharma are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Casper Pharma Private Limited, buy the company report.
Financials of Casper Pharma Private Limited
FY 2024 filings availableCasper Pharma Private Limited reported revenue of ₹30.43 Cr (up 151% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 32% over five years, including 151% growth in the latest year. EBITDA rose 84% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹30.43 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.51 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹8.34 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -8.3% | ||||
| Net Profit Margin | -27.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Casper Pharma Private Limited, buy the company report.
Board of directors of Casper Pharma Private Limited
Casper Pharma has 3 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Venkatanaga Kali Vetukuri Vara Prasada Raju Also directs: Deccan Fine Chemicals (India) Private Limited | Director | 01 Dec 2023 | 2 Years 11 Months | As last reported |
| Sudhir Kumar Singh | Whole-Time Director | 01 Dec 2023 | 2 Years 11 Months | As last reported |
| Himanshu Agarwal | Additional Director | 01 Aug 2024 | 2 Years 3 Months | As last reported |
Peer comparison
Casper Pharma Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Puneet Laboratories Private Limited | ₹30.72 Cr (FY 2025) | 25.0% | Mumbai, Maharashtra, India | |||
| Octavius Pharma Private Limited | ₹30.43 Cr (FY 2025) | 169.0% | Ahmedabad, Gujarat, India | |||
| Casper Pharma Private Limitedthis company | ₹30.43 Cr (FY 2024) | -₹8.34 Cr | -27.4% | 151.0% | 109 | Mumbai, Maharashtra, India |
| Ronald Pharmaceuticals Private Limited | ₹30.33 Cr (FY 2024) | -12.0% | Vadodara, Gujarat, India | |||
| Signova Healthcare Private Limited | ₹30.25 Cr (FY 2025) | 24.0% | Guwahati, Assam, India |
To see the full peer comparison of Casper Pharma Private Limited, buy the company report.
Auditor
Casper Pharma Private Limited is audited by K.Nagaraju and Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K.Nagaraju and Associates | FY 2024 | 002270S |
Shareholding
The shareholding of Casper Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Casper Pharma Private Limited, buy the company report.
Deals & funding
Casper Pharma Private Limited has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2022 | Rights issue | ₹41.73 Cr | Investors: Suven Pharmaceuticals Limited |
| Mar 2017 | Funding round | ₹104.27 Cr | Investors: Casper Pharma Mauritius |
| Mar 2017 | Secondary share transfer | Undisclosed | Buyer: Casper Pharma Mauritius, Casper Pharma Mauritius & Mallemputi Ramakrishna Chowdary Seller: Casper Pharma LLC, Casper Pharma LLC & Mallemputi Ramakrishna Chowdury |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Casper Pharma Private Limited has 1 court case on record: 1 filed by Casper Pharma. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLT | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLT, Mumbai | Court case (C.A.(CAA)) | Filed by the company | Disposed |
To see the full case history of Casper Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Casper Pharma Private Limited has 4 MSME Form 1 returns on record between 2020 and 2022, listing 42 overdue payments to 5 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 5)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Kinelectro Lines India Private Limited | |||
| Vasco Scientifics Private Limited | |||
| an individual supplier | |||
| Omega Scientific Instruments Private Limited | |||
| Himedia Laboratories Private Limited |
To see the full MSME payment records of Casper Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Casper Pharma Private Limited has a workforce of 109 employees on its EPFO records as of Jan 2025.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2024-25 | 109 |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 |
To see the full employee and EPFO history of Casper Pharma Private Limited, buy the company report.
GST
Casper Pharma has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAGCC3439C1ZY | Telangana | Active | 01 Jul 2017 |
| 36AAGCC3439C2ZX | Telangana | Active | 16 Mar 2021 |
To see the full GST registrations and return filing status of Casper Pharma Private Limited, buy the company report.
Recent activity
Casper Pharma Private Limited has 12 board changes on record since 2019: 3 appointments and 9 cessations. The latest: Himanshu Agarwal was appointed as Additional Director on 01 Aug 2024.
3 earlier events are in the company report.
Frequently asked questions
Casper Pharma has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Casper Pharma was a private limited company based in Mumbai, Maharashtra, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 13 January 2016 and is registered under CIN U24233MH2016PTC423891. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.
Casper Pharma was incorporated on 13 January 2016. It is registered with the Registrar of Companies, Mumbai.
Casper Pharma had 3 directors:
- Sudhir Kumar Singh - Whole-Time Director
- Venkatanaga Kali Vetukuri Vara Prasada Raju - Director
- Himanshu Agarwal - Additional Director
The CIN (Corporate Identification Number) of Casper Pharma is U24233MH2016PTC423891. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Casper Pharma is at 215 Atrium C Wing 8th Floor 819 – 821, Andheri Kurla Road Chakala Andheri East, Mumbai, Maharashtra, India – 400093.
Casper Pharma can be reached through the website cronuspharma.com. Its registered office is in Mumbai, Maharashtra, India.
The latest financial statements of Casper Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 01 August 2024. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Casper Pharma is 36AAGCC3439C1ZY, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AAGCC3439C2ZX (Telangana).
Casper Pharma operated in the pharma industry, in the drug formulation and development segment.
Casper Pharma has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹104.27 Cr; the latest was in June 2022.
The peers of Casper Pharma by revenue are Puneet Laboratories Private Limited, Octavius Pharma Private Limited, Ronald Pharmaceuticals Private Limited, Signova Healthcare Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

